hydroxychloroquine
羟氯喹
常用释义
英音[ haɪˈdrɒksɪˈklɔːrəkwiːn ]
美音[ haɪˈdrɑːksɪˈklɔːrəkwin ]
基本释义
- n. [药] 羟化氯喹
例句
-
1·Evidence for the safety of hydroxychloroquine was better vs chloroquine.证据显示羟氯喹的安全性较氯喹高。
-
2·Previous evidence from animal studies suggests that hydroxychloroquine has an antidiabetic effect.以前的动物研究表明，羟基氯喹具有抗糖尿病作用。
-
3·Of the 4905 patients included in this analysis, 1808 (37%) reported hydroxychloroquine use at some time during the observation period.该研究分析的4905名患者，其中有1808名(37%)报告曾在观测期内某段时间使用过羟基氯喹。
-
4·Incidence rates per 1000 patient-years of observation were 8.9 for never-users of hydroxychloroquine and 5.2 for ever-users (p < 0.001).未服用羟基氯喹的患者，糖尿病发病率为8.9/1000人年，而服过羟基氯喹的患者糖尿病发病率为5.2/1000人年（p < 0.001）。
-
5·Roughly one-third (1808) had taken hydroxychloroquine for some period of time during the study, with duration of treatment averaging 3.1 years.大约三分之一患者(1808)在研究的某个时期服用了羟基氯喹，平均服药时间3.1年。
-
6·Methotrexate plus hydroxychloroquine is recommended for patients with moderate to high disease activity regardless of disease duration or poor prognostic features.甲氨喋呤加羟氯喹的疗法是推荐给那些有中高度活动病情的患者，无论这些患者的病程长或短以及有无预后不良因素。
-
7·Putting together, we suggest that corticosteroids and hydroxychloroquine for treating SLE activity are able to control thyroid inflammation and hypothyroid function.总之，治疗全身性红斑狼疮而使用的皮质类固醇及氢氧奎宁可能可帮助控制甲状腺发炎及甲状腺功能低下症。
-
8·Also during this time, researchers recorded incident diabetes in 54 patients who had taken hydroxychloroquine at some point vs 171 patients who had never taken the drug.同样在这段时间，研究人员记录到曾在某个时间服用羟基氯喹的患者中有54名出现糖尿病，而从未服用该药的患者中有171名出现糖尿病。
-
9·Hydroxychloroquine plus sulfasalazine is recommended only for patients with intermediate disease duration (6-24 months) and high disease activity but without poor prognostic features.羟氯喹加柳氮磺吡啶疗法是只推荐给那些患病时间中等(6 - 24个月)，病情重但是没有不良预后特征的患者。
-
10·Overall, the hazard ratio for incident diabetes among patients who had taken hydroxychloroquine was 0.62% compared with those who had never taken it (95% confidence interval, 0.42-0.92).总的来说，服用羟基氯喹的患者与那些从未服用羟基氯喹的患者相比患糖尿病的风险比为0.62%(95%可信区间，0.42—0.92)。